Login to Your Account

Amgen Rises, AMAG Tumbles on CMS Dialysis Bundling Rule

By Donna Young

Wednesday, July 28, 2010
WASHINGTON – Tuesday's trading reflected investors' relief for Amgen Inc., ambiguity about Genzyme Corp. and anxiety over AMAG Pharmaceuticals Inc. on Medicare's release of the final rules governing payments for dialysis services for beneficiaries with end-stage renal disease (ESRD). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription